Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -22.15
- Piotroski Score 4.00
- Grade Neutral
- Symbol (VERO)
- Company Venus Concept Inc.
- Price $0.31
- Changes Percentage (2.21%)
- Change $0.01
- Day Low $0.31
- Day High $0.33
- Year High $2.22
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/31/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.68
- Trailing P/E Ratio -0.14
- Forward P/E Ratio -0.14
- P/E Growth -0.14
- Net Income $-37,250,000
Income Statement
Quarterly
Annual
Latest News of VERO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Venus Concept Inc (VERO) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Hemanth Varghese clarified that the body platform is not Aime and is set to launch in Q1 2025. Strong growth potential is noted in Australia, Mexico, and Hong Kong, with new partnerships in India driv...
By Yahoo! Finance | 4 days ago -
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Over 5,000 unique patients have been prescribed Ohtuvayre, with increasing refills and patient adds. Prescriber trends show a broad range of therapy combinations. Infrastructure for patient access is ...
By Yahoo! Finance | 1 week ago -
Roma's spooky season lingers as Ivan Juric haunted by return to Verona | Nicky Bandini
Roma's coach faces pressure after a loss against his former club. Juric's tenure may be in jeopardy as Roma struggles to live up to fans' expectations post-De Rossi era. Financial pressure and poor pe...
By The Guardian | 2 weeks ago
